Bronchial responsiveness to hyperventilation in children with asthma: inhibition by ipratropium bromide.
AUTOR(ES)
Wilson, N
RESUMO
Isocapnic hyperventilation dose response curves were constructed for 11 asthmatic children before and after pretreatment with placebo or ipratropium bromide, 40-1500 micrograms given by inhalation, on three separate days. The response before and after placebo was highly reproducible (within subject coefficient of variation 7.5%, 18%, and 22% for intervals of two hours, within two weeks, and over two weeks). It was independent of baseline lung function. Complete protection against hyperventilation induced asthma was achieved by ipratropium bromide 40 micrograms in six children and by 200 micrograms or more in a further four. The remaining child was unaffected by any dose of ipratropium up to 1500 micrograms. The dose of ipratropium required for protection was better related to the subjects' requirement for regular medication than to their sensitivity to hyperventilation or baseline lung function.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1020510Documentos Relacionados
- Ipratropium bromide in children with asthma.
- Supraventricular tachycardia caused by nebulised ipratropium bromide.
- Failure of ipratropium bromide to modify the diurnal variation of asthma in asthmatic children.
- Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness.
- Bronchial gland duct ectasia in fatal bronchial asthma: association with interstitial emphysema.
